CLINICAL TRIALS PROFILE FOR MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM SULFATE
✉ Email this page to a colleague
All Clinical Trials for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02124447 ↗ | Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy | Withdrawn | Medical College of Wisconsin | N/A | 2014-06-01 | This will be a 4-way comparison to prospectively evaluate the efficacy and patient tolerability of four commercially available bowel preparations among patients undergoing colonoscopy for screening and surveillance in a single tertiary academic medical center. |
| NCT02663895 ↗ | Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis | Completed | United Therapeutics | Phase 2 | 2016-10-01 | This is a prospective open-label trial that will enroll 12 patients with systemic sclerosis (SSc) and at least one calcinotic lesion of the hands that is palpable on physical examination and also measureable on hand radiographs, at one single center. Each subject will receive treprostinil orally for 12 months, and follow-up evaluations will be performed every 3 months. Our main objective is to determine whether oral treprostinil is safe, and effective in reducing calcinosis in patients with SSc. We hypothesize that calcinosis is a result of microvascular injury and ischemic damage, and that therefore treprostinil may be beneficial in the treatment of calcinosis in patients with SSc. |
| NCT02663895 ↗ | Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis | Completed | Stanford University | Phase 2 | 2016-10-01 | This is a prospective open-label trial that will enroll 12 patients with systemic sclerosis (SSc) and at least one calcinotic lesion of the hands that is palpable on physical examination and also measureable on hand radiographs, at one single center. Each subject will receive treprostinil orally for 12 months, and follow-up evaluations will be performed every 3 months. Our main objective is to determine whether oral treprostinil is safe, and effective in reducing calcinosis in patients with SSc. We hypothesize that calcinosis is a result of microvascular injury and ischemic damage, and that therefore treprostinil may be beneficial in the treatment of calcinosis in patients with SSc. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
Condition Name
| Condition Name for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate | |
| Intervention | Trials |
| Bowel Preparation for Colonoscopy | 1 |
| Calcinosis | 1 |
| Colonoscopy | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Condition MeSH
Clinical Trial Locations for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
Trials by Country
Clinical Trial Progress for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate
Sponsor Name
| Sponsor Name for magnesium sulfate; polyethylene glycol 3350; potassium chloride; sodium chloride; sodium sulfate | |
| Sponsor | Trials |
| First affiliated hospital of Nanchang University | 1 |
| Hebei Provincial People's Hospital | 1 |
| Henan Provincial People's Hospital | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
